Target

CD40

Tumor necrosis factor receptor superfamily member 5

12open trials
28trials in total
144publications
0researchers

Diseases

The last 24 months

New trials, publications, preprints and grants on this target, month by month.

TrialsPublicationsPreprintsGrants

Publication
CD40-CD40L interactions in systemic autoimmune diseases.
16 Oct 2026· Rheumatology (Oxford, England)· PUBMED
Publication
A dual-function XCL1-CD40L mRNA adjuvant potentiates cancer vaccines by coordinating DC recruitment and maturation.
14 Oct 2026· Frontiers in immunology· PUBMED
Publication
Oncolytic virus encoding decorin and the CD40 ligand boosts T-cell response and achieves a durable antitumor response during breast cancer treatment.
5 Oct 2026· Molecular biomedicine· PUBMED
Publication
Phase 1 dose escalation and expansion trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein SL-172154 (SIRPα-Fc-CD40L) in patients with higher-risk myelodysplastic syndrome or acute myeloid leukemia.
1 Oct 2026· Cancer· PUBMED
Publication
Pediatric Brain Tumor Consortium Phase I Study of CD40 Agonist Sotigalimab in Pediatric and Young Adult Patients with Recurrent CNS Tumors and Newly Diagnosed DIPG.
1 Oct 2026· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED
Publication
The Association Between CD40 rs1883832 Polymorphism and Cancer Susceptibility: A Systematic Review and Meta-Analysis.
1 Oct 2026· Cancer medicine· PUBMED
Publication
Identification of CD40 as the target of artemisinin via targeted degradomics for ulcerative colitis.
28 Sept 2026· Bioorganic chemistry· PUBMED
Publication
Genetic evidence supports the prioritization of CD40 among prespecified immune-related candidate drug targets in myasthenia gravis.
16 Sept 2026· The International journal of neuroscience· PUBMED
Trial
A Study of 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma
4 Sept 2026· PHASE1_PHASE2 · RECRUITING· CTGOV
Publication
Agonistic anti-CD40 antibodies in patients with solid tumors: a systematic review and evidence map of clinical safety, with exploratory proportional synthesis.
27 Aug 2026· Frontiers in immunology· PUBMED
Publication
Divergent Immune and Endothelial Responses to Insulin Resistance in Women with Polycystic Ovary Syndrome.
21 Aug 2026· International journal of molecular sciences· PUBMED
Publication
L-asparaginase reversibly suppresses CD40-mediated B cell activation and antigen-presenting function by metabolic restriction.
11 Aug 2026· iScience· PUBMED
Publication
Enhanced antitumor efficacy through combined chimeric antigen receptor T cell therapy and CD40 stimulation in syngeneic solid tumor models.
6 Aug 2026· Cytotherapy· PUBMED
Publication
Antigen presentation by CD40+MHC-II+ astrocytes promotes CNS autoimmunity.
5 Aug 2026· Nature· PUBMED
Preprint
Identifying the causal allele in the CD40 autoimmune locus enables discovery of context-specific trans-effects in B cells.
4 Aug 2026· bioRxiv : the preprint server for biology· PUBMED
Publication
Tumor Microenvironment Gene Engineering with LOAd703 in Patients with Solid Malignancies: LOKON002 Phase I/IIb Clinical Trial.
3 Aug 2026· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED
Publication
Nanoparticle-enabled CD40 silencing programs immune tolerance via a DC-Treg-Breg axis in autoimmune myocarditis.
3 Aug 2026· Materials today. Bio· PUBMED
Preprint
Dual stimulation of CD40 and 41BB pathways during ex-vivo TIL expansion enhances CD8+ T cell expansion.
26 Jul 2026· bioRxiv : the preprint server for biology· PUBMED
Publication
Soluble CD40 Levels in Rheumatoid Arthritis: Association with Serum Cytokines and Autoantibody Status.
26 Jul 2026· Journal of clinical medicine· PUBMED
Publication
Tumor-targeted CD40 ligand-functionalized extracellular vesicle mimetics enable chemoimmunotherapy for neuroblastoma.
24 Jul 2026· Journal of controlled release : official journal of the Controlled Release Society· PUBMED
Publication
Dendritic cells control tertiary lymphoid structure development and maintenance in cancer.
16 Jul 2026· Science (New York, N.Y.)· PUBMED
Publication
Lowering CD40L expression in murine lupus results in an increase in disease indicators in female but not male B6 mice.
10 Jul 2026· Journal of immunology (Baltimore, Md. : 1950)· PUBMED
Publication
Reduced Tumor Control in Males Can Result from Impaired CD4+ T-cell Help through the CD40L-CD40 Pathway.
2 Jul 2026· Cancer immunology research· PUBMED
Publication
Cytokine profiles in patients with chronic kidney disease and low sexual function.
2 Jul 2026· American journal of physiology. Renal physiology· PUBMED
Publication
Retraction Note: Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells.
1 Jul 2026· Nature immunology· PUBMED
Publication
CD40 Agonist Therapy in Melanoma: Translating Preclinical Promise Into Clinical Practice.
1 Jul 2026· Pigment cell & melanoma research· PUBMED
Publication
CD40 agonism in renal cell carcinoma enhances immune checkpoint activity through myeloid cells.
29 Jun 2026· iScience· PUBMED
Publication
Diabetes mellitus exacerbates myasthenia gravis by upregulating CD40 expression on B cells through the RAGE-HIF-1α-HK2 pathway.
29 Jun 2026· Journal of neuroimmunology· PUBMED
Publication
Exploratory Diagnostic Performance of On-Admission Soluble CD40 Ligand for Distinguishing Acute Pulmonary Embolism from Hospitalization-Requiring Community-Acquired Pneumonia: A Single-Center Observational Study.
16 Jun 2026· Diagnostics (Basel, Switzerland)· PUBMED
Publication
Limited efficacy of a therapeutic anti-CD40 monoclonal antibody to inhibit activated CD4 T cell autoimmunity in vitro.
12 Jun 2026· PloS one· PUBMED

Who works on it

Researchers who published on this target. Leave out your own co-author circle to find people you do not know yet.

No published researcher profile on this target yet.

We look for a fixed list of target names in titles, keywords, intervention names and MeSH terms. A mention does not prove that the work is aimed at that target.

Report an error